As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
Anthropic says Claude found a new enzyme system that resembles CRISPR. Here is what it means for Beam Therapeutics and whether BEAM stock looks like a buy.
Barchart ·